Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018133 (graft-versus-host disease)
 18,032 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The transfusion service (TS) plays an important role in bone marrow transplantation (BMT). Many of the techniques and methods employed are also used in the daily work of a TS like tissue typing, apheresis techniques, handling of blood and its components under sterile conditions. In the pretransplantation phase the TS is responsible for the typing of recipient and presumptive donors, harvesting of autologous blood and selection of appropriate blood components. During BMT the TS can perform bone marrow harvesting, depletion of red cells in case of ABO-incompatibility and bone marrow manipulation when T-cell depletion or purging procedures are considered. Peripheral stem cell harvest by apheresis is also best performed by the TS experienced in such techniques. Storage of hematopoietic cells in liquid nitrogen and thawing are also techniques already used in most of the transfusion services. Post BMT, the support with blood components, irradiated and almost free of white cells to avoid TA-GVH and CMV-infection, is a major job of the TS. These facts demonstrate that a well organized transfusion service is a 'conditio sine qua non' for successful BMT.
 ...
PMID:[The role of blood banks in bone marrow transplantation]. 172 36

Between September 1985 and June 1990, five patients with major and six patients with minor ABO blood group incompatibility between donor and recipient underwent allogeneic bone marrow transplantation (BMT) in the Singapore General Hospital. The period to engraftment, rate of recovery of peripheral blood leukocytes, granulocytes, and platelets and the incidence of graft versus host disease (GVHD) was similar to that observed following ABO blood group compatible marrow transplant. Erythroid development and reticulocytosis were, however, significantly delayed in patients receiving major ABO incompatible marrow transplant.
 ...
PMID:A preliminary report on ABO incompatible bone marrow transplant. 179 51

Three groups of patients with leukaemia and myelodysplasia were assessed with regard to the blood product support they required during their period of bone marrow hypoplasia following treatment. One group received myelo-ablative remission-induction chemotherapy followed by appropriate consolidation therapy (two courses in patients with acute myeloid leukaemia and one or two intensification courses in patients with acute lymphoblastic leukaemia); whilst the other two had 'conditioning' with chemotherapy and radiotherapy prior to autologous bone marrow transplantation (auto-BMT) or T cell depleted allogeneic bone marrow transplantation (allo-BMT). There was no statistically significant difference in blood product requirements between the three groups. However, platelet requirements during remission-induction chemotherapy alone were significantly less than for allo-BMT or auto-BMT. Platelet requirements for patients undergoing auto-BMT were also significantly higher than for patients receiving consolidation chemotherapy; and were required for a longer period than for patients receiving allogeneic-BMT. There was no difference in blood product support between ABO matched and mismatched transplants within the allogeneic group, but the presence of graft versus host disease and/or cytomegalovirus infection did significantly increase the requirements for blood product support.
 ...
PMID:Blood product support in patients undergoing chemotherapy and autologous or allogeneic bone marrow transplantation for haematological malignancies. 193 21

There is no general agreement about the effect of an enlarged spleen on the outcome after bone marrow transplantation (BMT) for chronic myeloid leukaemia (CML). In this retrospective analysis, we compared rate of engraftment, haematological recovery and survival in 42 CML BMT recipients, 19 with splenomegaly and 23 without. Other variables analysed included interval from diagnosis to BMT, disease status at BMT, conditioning regimen, additional splenic irradiation, marrow cell dose, donor recipient ABO match and graft-versus-host disease. In multivariate analysis, the only significant variable was the presence or absence of splenomegaly. Splenomegaly was significantly correlated with delayed engraftment and graft failure. Patients with delayed engraftment experienced higher mortality, largely due to sepsis. These results emphasize the adverse impact of splenomegaly upon BMT survival in CML, and suggest that splenic irradiation does not favourably affect the early outcome after BMT.
 ...
PMID:Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. 233 36

An analysis of the transfusion records of 91 neonatal patients subjected to extracorporeal membrane oxygenation (ECMO) is reported. Mean daily blood usage was 250 mL of red cells (RBCs), 80 mL of fresh-frozen plasma, and 2 units of platelets. Average time on ECMO was 4.6 days. Group O or ABO type-specific RBCs and group AB or ABO type-specific plasma products and platelets were transfused. RBCs were not washed, and neither RBCs nor other components were tested for anticytomegalovirus (CMV) or irradiated. No cases of posttransfusion CMV infection or graft-versus-host disease were observed. Hemolysis in eight patients was traced to occlusions in the ECMO circuit. All but three patients survived ECMO. Contrary to a previous report, an active ECMO program for neonatal patients imposes a minimal burden on the hospital transfusion service.
 ...
PMID:Blood use during extracorporeal membrane oxygenation. 204 88

From 1976 through 1985, the United States Food and Drug Administration received reports of 355 fatalities associated with transfusion, 99 of which were excluded from further review because they were unrelated to transfusion or involved hepatitis or acquired immune deficiency syndrome. Of the remaining 256 reported deaths, 51 percent resulted from acute hemolysis following the transfusion of ABO-incompatible products. These deaths were due primarily to managerial, not clerical, errors. Other causes of death (in order of frequency of report) included acute pulmonary injury (15%), bacterial contamination of product (10%), delayed hemolysis (10%), damaged product (3%), and graft-versus-host disease (0.4%). Management systems for transfusion facilities should be created or revised to include the specific identification of personnel eligible to administer transfusions to provide written guidance and appropriate training (including recognition and management of errors), and to implement measures that target safe transfusion practices. Continued research into acute pulmonary injury, the immunologic hazards of transfusion, and the prevention of bacterial contamination of blood components is necessary.
 ...
PMID:Reports of 355 transfusion-associated deaths: 1976 through 1985. 240 71

23 bone marrow transplant recipients whose donors where major ABO-incompatible received marrow depleted of red cells prior to infusion utilizing gravity sedimentation in hydroxyethyl starch. The in vitro red cell-depletion procedure effectively removed 97.8% (mean) of the red cells from the harvested marrows and preserved 86.8% of the nucleated cells and 98.2% of the CFU-C activity in 25.4% of the original volume. All recipients had a significant quantity of isohemagglutinins of both IgM and IgG classes demonstrable in their serum at the time of the marrow infusion. Patients were premedicated and well-hydrated prior to the infusion and tolerated the infusion well. These patients demonstrated bone marrow engraftment at the same rate as did those patients whose marrow donors were either ABO-identical or minor ABO-incompatible. There was no difference in the incidence of or time to development of graft versus host disease, the incidence of graft rejection, or patient survival among the groups. Recipients of red cell-depleted major ABO-incompatible bone marrow transplants demonstrated production of donor-type red cells somewhat later and required slightly more red cell transfusion support that did the other groups of recipients. This red cell-depletion technique is safe and effective in the management of major ABO-incompatible bone marrow transplantation.
 ...
PMID:Transplantation of major ABO-incompatible bone marrow depleted of red cells by hydroxyethyl starch. 241 22

Plasma glycosyltransferase activities were studied in eight patients after ABO-incompatible bone marrow transplantation. The ABO red blood cell type completely changed from the recipient type to the donor type; however, preexistent plasma glycosyltransferase activities of the recipient type did not change in seven of eight patients after marrow transplantation. Weak transferase activities of the donor type were observed in all of the patients after marrow grafting. One patient with acute and chronic graft-versus-host disease produced a very potent inhibitor that was active on both A- and B-transferase activities. Because this inhibitory activity was absorbed by a protein A-coupled Sepharose column, it was strongly suggested that this inhibitory activity was mediated by an IgG antibody for a transferase.
 ...
PMID:Plasma glycosyltransferase activity after ABO-incompatible bone marrow transplantation and development of an inhibitor for glycosyltransferase activity. 250 24

The development of methods for the production of monoclonal antibodies is having an important impact in the field of immunohaematology. Four separate areas are implicated. First, there is the use of monoclonal antibodies in blood transfusion, where antibodies within the ABO, Rh, Lewis, P, MN, Kell and Lutheran systems are available. Most of the monoclonal antibodies are of murine origin but the techniques for producing human monoclonal antibodies is now well established and this is especially valuable in the Rh system, with the production so far of anti-c, D, -E, -e and -G. Secondly, there is a great potential for the use of monoclonal anti-D to substitute for polyclonal anti-D in the prophylaxis of haemolytic disease of the newborn. The introduction of these antibodies will depend on clinical trials using both the IgG1 and IgG3 subclasses and on the ability to prepare antibody which is free of viruses and DNA. Thirdly, monoclonal antibodies are being used in basic research on red cell membranes to isolate and characterise blood group antigens. Finally, these antibodies are being used in bone marrow transplantation to purge the donor marrow of T-cells in order to reduce the incidence of graft-versus-host disease.
 ...
PMID:Monoclonal antibodies in haematology. 265 Jul 76

A Y-chromosome-specific in situ hybridization assay was used to assess the frequency with which host bone marrow cells are retained after marrow grafting. The majority of patients (74%) showed the presence of both host and donor marrow cells when assayed 14 days after transplant. By 84 days posttransplant only 4% of the patients retained host marrow cells. Only 1 of 19 evaluable patients analyzed over 1 year posttransplant showed minimal retention of host cells. No statistical correlation was found between retention of host cells posttransplant and the development of relapse or acute or chronic graft-versus-host disease. Pretransplant conditioning regimen, HLA-matching, diagnosis, disease status at transplant, ABO-matching, and patient age also showed no correlation with the retention of host cells posttransplant.
 ...
PMID:Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. 280 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>